Jami Mannle
Family · O Fallon, ILNPI 1184857674
Payments from drug & device makers
Across 401 payments — averaging $16.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Johnson & Johnson$737
- Amgen$554
- Incyte Corporation$454
- Lilly USA, LLC$380
- Pfizer$311
- plus $2K from 14 others
What the payments were for
- Food & beverage$6,16994%
- Education$4136%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 152 | $2,206 |
| Johnson & Johnson | 27 | $737 |
| Amgen | 29 | $554 |
| Incyte Corporation | 30 | $454 |
| Lilly USA, LLC | 22 | $380 |
| Pfizer | 17 | $311 |
| E.r. Squibb & Sons, L.L.C. | 26 | $304 |
| UCB, Inc. | 13 | $262 |
| Novartis | 8 | $238 |
| Dermavant Sciences, Inc. | 26 | $198 |
| LEO Pharma Inc. | 9 | $191 |
| Sanofi | 9 | $163 |
| Galderma Laboratories, L.p. | 8 | $123 |
| Arcutis Biotherapeutics, Inc. | 6 | $123 |
| Sun Pharmaceutical Industries Inc. | 6 | $107 |
| Sanofi-aventis U.S. LLC | 1 | $80 |
| Regeneron Healthcare Solutions, Inc. | 3 | $62 |
| Mayne Pharma Commercial LLC | 2 | $40 |
| Organon | 6 | $33 |
| Biofrontera Inc. | 1 | $16 |
How this compares
$6,582 in reported general payments places this provider in the 95th percentile of 4,941 family providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 19 | $404,197 |
| Dupixent PenDupilumab | 17 | $127,952 |
| Xeljanz XrTofacitinib Citrate | 13 | $73,843 |
| Tacrolimus | 29 | $5,260 |
| Clobetasol Propionate | 70 | $2,881 |
| Hydroxyzine Hcl | 89 | $1,649 |
| Ketoconazole | 85 | $1,536 |
| Fluorouracil | 19 | $1,338 |
| Triamcinolone Acetonide | 133 | $1,328 |
| Tretinoin | 13 | $1,109 |
| Minocycline Hcl | 65 | $987 |
| Glycopyrrolate | 12 | $871 |
| ValacyclovirValacyclovir Hcl | 21 | $715 |
| Metronidazole | 11 | $607 |
| Doxycycline Hyclate | 25 | $575 |
Paid to pharmacies, not to this prescriber.
Other family in O Fallon
- Jennifer MartensO Fallon$159K
- Amy BuckO Fallon$26K
- Ruth CarricoChicago$582K
- Aleksandra BielawiecBarrington$373K
- Erin SieberNaperville$334K
- Jamie BroganChicago$282K
- Ashley NoethGlen Carbon$271K
- Marita KametasChicago$259K
- Shammona ClarkChicago$247K
- Amanda McKeeMount Vernon$242K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.